Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Procaps Group SA (PROC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PROC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.16% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 113.95M USD | Price to earnings Ratio 1.53 | 1Y Target Price 5 |
Price to earnings Ratio 1.53 | 1Y Target Price 5 | ||
Volume (30-day avg) 22930 | Beta 0.17 | 52 Weeks Range 0.50 - 3.77 | Updated Date 04/1/2025 |
52 Weeks Range 0.50 - 3.77 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.66 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.61% | Operating Margin (TTM) 11.13% |
Management Effectiveness
Return on Assets (TTM) 6.28% | Return on Equity (TTM) 37.37% |
Valuation
Trailing PE 1.53 | Forward PE 81.3 | Enterprise Value 429940549 | Price to Sales(TTM) 0.28 |
Enterprise Value 429940549 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 1.04 | Enterprise Value to EBITDA 3.48 | Shares Outstanding 112824000 | Shares Floating 17150379 |
Shares Outstanding 112824000 | Shares Floating 17150379 | ||
Percent Insiders 83.03 | Percent Institutions 2.93 |
Analyst Ratings
Rating 3 | Target Price 5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Procaps Group SA
Company Overview
History and Background
Procaps Group SA is a pharmaceutical and nutraceutical company focused on developing, manufacturing, and marketing pharmaceutical solutions. Founded in Colombia, Procaps has expanded its global reach and product portfolio over the years.
Core Business Areas
- Softgel Manufacturing: Development, manufacturing, and marketing of soft gelatin capsules for pharmaceutical and nutraceutical applications.
- Oral Solid Dosage: Manufacturing of tablets, capsules, and powders.
- Hospital Solutions: Production and distribution of injectable solutions and other hospital supplies.
- OTC (Over-the-Counter) Products: Development and marketing of OTC medications and consumer healthcare products.
Leadership and Structure
The company is led by a board of directors and an executive management team, responsible for strategic direction and operational execution. The organizational structure includes functional departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Product Name 1: Softgel Capsules: Used for various pharmaceutical and nutraceutical applications. Market share data varies regionally, with Procaps being a significant player in Latin America. Competitors: Catalent, Lonza.
- Product Name 2: Oral Solid Dosage Forms: Including tablets and capsules for different therapeutic areas. Competitors: Teva Pharmaceuticals, Mylan (Viatris).
Market Dynamics
Industry Overview
The pharmaceutical and nutraceutical industries are experiencing growth due to aging populations, increasing healthcare spending, and a focus on preventive care.
Positioning
Procaps is positioned as a vertically integrated player with strong manufacturing capabilities and a focus on innovative drug delivery systems.
Total Addressable Market (TAM)
The global pharmaceutical market size is estimated at over $1 trillion. Procaps is positioned to capture a segment of this TAM through its specialized manufacturing and product offerings.
Upturn SWOT Analysis
Strengths
- Strong manufacturing capabilities
- Vertically integrated operations
- Established presence in Latin America
- Innovative drug delivery technologies
- Diverse product portfolio
Weaknesses
- Geographic concentration in Latin America
- Reliance on a few key customers
- Exposure to currency fluctuations
- Limited brand recognition in some markets
Opportunities
- Expanding into new geographic markets
- Acquiring complementary businesses
- Developing new products and formulations
- Partnering with pharmaceutical companies
- Growing demand for softgel technology
Threats
- Increased competition
- Regulatory changes
- Economic downturns
- Patent expirations
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Catalent (CTLT)
- Lonza (LZAGY)
- Teva Pharmaceutical Industries Ltd (TEVA)
- Viatris (VTRS)
Competitive Landscape
Procaps has a strong manufacturing footprint in Latin America, allowing for cost advantages. Its innovative drug delivery technologies provide a competitive edge. Weaknesses include geographical concentration and reliance on few customers.
Major Acquisitions
Sofigel
- Year: 2021
- Acquisition Price (USD millions): 60
- Strategic Rationale: Expanded softgel manufacturing capabilities and product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends have been driven by organic expansion and strategic acquisitions.
Future Projections: Future growth is expected to be driven by expansion into new markets, product innovation, and strategic partnerships. Analyst estimates are not included due to data availability.
Recent Initiatives: Recent strategic initiatives include expanding manufacturing capacity and entering new geographic markets.
Summary
Procaps Group SA demonstrates strengths in its manufacturing capabilities and Latin American presence but faces challenges due to its geographic concentration and reliance on key customers. The company is positioned to leverage its innovative technologies to expand into new markets. Monitoring competitor activities and economic trends is crucial for continued growth. While the company is growing, it should focus on diversification to mitigate its risks.
Similar Companies
CTLT
Catalent Inc
CTLT
Catalent Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
VTRS
Viatris Inc
VTRS
Viatris Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Financial data limitations may exist.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Procaps Group SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-09-30 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 5500 | Website https://www.procapsgroup.com |
Full time employees 5500 | Website https://www.procapsgroup.com | ||
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.